Evidence map›Paper›PMID 40426665›Full record

ReviewBrain sciences2025

AI-Driven Advances in Parkinson's Disease Neurosurgery: Enhancing Patient Selection, Trial Efficiency, and Therapeutic Outcomes.

José E Valerio, Guillermo de Jesús Aguirre Vera, Maria P Fernandez Gomez, Jorge Zumaeta, Andrés M Alvarez-Pinzon

Abstract readReview
In one paragraph

Review in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

José E ValerioNeurosurgery Innovation and Technology Division, Latinoamerica Valerio Foundation, Weston, FL 33331, USA.ORCID 0000-0001-7283-5988
Guillermo de Jesús Aguirre VeraNeurosurgery Innovation and Technology Division, Latinoamerica Valerio Foundation, Weston, FL 33331, USA.ORCID 0009-0001-4689-7058
Maria P Fernandez GomezNeurosurgery Innovation and Technology Division, Latinoamerica Valerio Foundation, Weston, FL 33331, USA.ORCID 0000-0002-9506-5282
Jorge ZumaetaNeurosurgery Innovation and Technology Division, Latinoamerica Valerio Foundation, Weston, FL 33331, USA.ORCID 0009-0007-9471-167X
Andrés M Alvarez-PinzonNeurosurgery Innovation and Technology Division, Latinoamerica Valerio Foundation, Weston, FL 33331, USA.ORCID 0000-0003-3488-8020

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by motor and non-motor dysfunctions that severely compromise patients' quality of life. While pharmacological treatments provide symptomatic relief in the early stages, advanced PD often requires neurosurgical interventions, such as deep brain stimulation (DBS) and focused ultrasound (FUS), for effective symptom management. A significant challenge in optimizing these therapeutic strategies is the early identification and recruitment of suitable candidates for clinical trials. This review explores the role of artificial intelligence (AI) in advancing neurosurgical and neuroscience interventions for PD, highlighting the ways in which AI-driven platforms are transforming clinical trial design and patient selection. Machine learning (ML) algorithms and big data analytics enable precise patient stratification, risk assessment, and outcome prediction, accelerating the development of novel therapeutic approaches. These innovations improve trial efficiency, broaden treatment options, and enhance patient outcomes. However, integrating AI into clinical trial frameworks presents challenges such as data standardization, regulatory hurdles, and the need for extensive validation. Addressing these obstacles will require collaboration among neurosurgeons, neuroscientists, AI specialists, and regulatory bodies to establish ethical and effective guidelines for AI-driven technologies in PD neurosurgical research. This paper emphasizes the transformative potential of AI and technological innovation in shaping the future of PD neurosurgery, ultimately enhancing therapeutic efficacy and patient care.

Indexed as

artificial intelligenceclinical trialsmachine learningneurodegenerative disordersParkinson’s disease

Identifiers

PMID40426665
PMCPMC12110375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.